Drugs / SENL103
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial · 1 met primary | ||||||
| Phase 0 | NCT06067581 | Aug 2023 → Aug 2025 | plasma cell myeloma | Hebei Senlang Biotechnology Inc., Ltd. | Unknown | Met primary |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT07421856 | Feb 2026 → Feb 2028 expected | plasma cell myeloma | Hebei Senlang Biotechnology Inc., Ltd. | Not yet recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SENL103 | “A Multicenter, Open-label, Single-Arm Phase I/II Clinical Study to Evaluate the Safety and Efficacy of SENL103 Autologous T Cell Injection (S103) in Subjects With Relapsed or...” NCT07421856 ↗ |
| Known as | S103 | “A Multicenter, Open-label, Single-Arm Phase I/II Clinical Study to Evaluate the Safety and Efficacy of SENL103 Autologous T Cell Injection (S103) in Subjects With Relapsed or...” NCT07421856 ↗ |
| Modality | Cell therapy | “Patients will be treated with BCMA CAR-T cells” NCT06067581 ↗ |
| Route | Intravenous | “after intravenous infusion of SENL103” NCT06067581 ↗ |